These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12410061)

  • 1. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
    Rosse RB; Deutsch SI
    Clin Neuropharmacol; 2002; 25(5):272-5. PubMed ID: 12410061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.
    Bora E; Veznedaroğlu B; Kayahan B
    Clin Neuropharmacol; 2005; 28(3):139-41. PubMed ID: 15965314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
    Lilienfeld S
    CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
    Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
    CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nicotinic Receptor, galantamine and Alzheimer disease].
    Arroyo G; Aldea M; Fuentealba J; García AG
    Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.
    Arnold DS; Rosse RB; Dickinson D; Benham R; Deutsch SI; Nelson MW
    J Clin Psychiatry; 2004 Dec; 65(12):1723-4. PubMed ID: 15641883
    [No Abstract]   [Full Text] [Related]  

  • 11. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Galantamine (reminyl) in the treatment of severe Alzheimer's disease].
    Gavrilova SI; Kolykhanov IV; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):57-61. PubMed ID: 19672237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
    Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
    Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic cholinergic modulation: galantamine as a prototype.
    Woodruff-Pak DS; Lander C; Geerts H
    CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine hydrobromide: an agent for Alzheimer's disease.
    Zarotsky V; Sramek JJ; Cutler NR
    Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine for treatment-resistant schizophrenia.
    Allen TB; McEvoy JP
    Am J Psychiatry; 2002 Jul; 159(7):1244-5. PubMed ID: 12091212
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
    Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R
    J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.